For a while now, researchers have speculated that RNA interference might be able to be boost the efficacy of small molecule drugs, such as cancer treatments. A paper in the most recent issue of the Journal of Clinical Investigation adds to the growing body of evidence supporting this theory, in demonstrating how stable expression of siRNAs in hematopoietic cells appears to increase the efficacy of Novartis’ Gleevec.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.